Fruquintinib - Hutchison MediPharma

Drug Profile

Fruquintinib - Hutchison MediPharma

Alternative Names: HMPL-013

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Gastric cancer; Non-small cell lung cancer
  • Phase II Solid tumours

Most Recent Events

  • 31 Oct 2017 Phase-III clinical trials in Gastric cancer (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT03223376)
  • 16 Oct 2017 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer released by Hutchison China MediTech
  • 29 Sep 2017 Efficacy data from the FRESCO phase III trial in Colorectal cancer released by Hutchison MediPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top